ARCHIVES

Cancer Organizations Continue Reform Lobbying: Target Issue Are Off-Label Drugs, Clinical Trials

This article is from The Cancer Letter archive.

Vol. 19 No. 13 | March 26, 1993

Download PDF Visit The Full Archive

Related Articles

Study Finds Nearly Two-Thirds Of Children Return to Hospital Following Stem Cell Transplant

April 26, 2013

ASCO Calls For New Clinical Study Section, Endorses NCAB Action In Senate Testimony

July 23, 1993

Avastin doubles progression-free survival in metastatic disease.

May 27, 2005

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

April 25, 2014

BSA, BSC Approve Concept for NCI Scholars Program

March 7, 1997

Clinical Education Guidelines Proposed

April 4, 1975